Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

Zhao, Na; Yang, Yuan; Zhang, Ling; Zhang, Qinge; Balbuena, Lloyd; Ungvári, Gábor S.; Zang, Yu; Xiang, Yu Tao

doi:10.1111/cns.13549

Cited by 69 publications

(46 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…QoL is considered a vital outcome indicator in patients with PD [ 29 ]. A broad list of motor and non-motor symptoms was shown to be important contributors to QoL in patients with PD [ 30 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of Cerebral Microbleeds on Cognitive Function and Quality of Life in Parkinson Disease

et al. 2022

View full text Add to dashboard Cite

Background This study aimed to investigate the risk factors and patterns of cerebral microbleeds (CMBs) in Parkinson disease (PD) and the impact of CMBs on cognitive function and quality of life (QoL). Material/Methods Patients with PD that underwent susceptibility-weighted imaging were recruited and divided into CMB-free, lobar-CMB, deep-CMB, and mixed-CMB groups according to CMB location. Motor function (MDS-UPDRS III), cognitive abilities (MoCA, MMSE), and QoL (PDQ-39) were compared among groups. The risk factors for CMBs in patients with PD and the association between CMBs and cognition and QoL were analyzed using multivariable logistic regression models and linear regression models. Results Among the 209 patients with PD, 42 (20.1%) had CMBs. Lobar, deep, and mixed CMBs were observed in 15 (35.7%), 17 (40.5%), and 10 (23.8%) patients, respectively. A higher frequency of hypertension was independently associated with deep CMBs (odds ratio [OR]=4.379, 95% CI: 1.405–13.643, P =0.011). The deep-CMB and mixed-CMB groups had lower MoCA scores and MMSE scores than the CMB-free group, especially in domains of naming, attention, and orientation ( P <0.05). Additionally, the presence of CMBs was associated with lower MMSE (R 2 =0.140, β=−0.301, P <0.001) and MoCA (R 2 =0.104, β=−0.289, P <0.001) and higher PDQ-39 (R 2 =0.052, β=0.227, P <0.05) scores, while the association between CMBs and PDQ-39 disappeared after adjustment of MMSE or MoCA as a covariate. Conclusions The results suggest that hypertension was associated with the occurrence of deep CMBs. Comorbidity with CMBs may impair cognitive function and indirectly reduce the QoL in patients with PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Cerebral Microbleeds on Cognitive Function and Quality of Life in Parkinson Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This concomitant depressive symptomatology is ultimately crucial for explaining why nonadherence and decreased medication knowledge contribute to a poorer HRQoL, which is in turn associated with increased nonadherent behavior, such as intentional nonadherence (i.e., changing medications without consulting the physician). Depression has been shown to strongly influence HRQoL [39,40]; however, the exact effect of depression is not yet fully understood, especially with regard to the complex association among worse health status, health literacy, and depression [41]. A previous study reported that, while depressed patients showed significantly worse health status, low health literacy itself did not predict depressive symptomology [42].…”

Section: Discussionmentioning

confidence: 99%

The impact of poor medication knowledge on health-related quality of life in people with Parkinson’s disease: a mediation analysis

et al. 2021

View full text Add to dashboard Cite

Purpose This study aimed to determine how limited medication knowledge as one aspect of health literacy contributes to poorer health-related quality of life (HRQoL) in people with Parkinson’s disease (PD). Methods Demographical data, PD-specific data (MDS-Unified Parkinson’s Disease-Rating Scale, Nonmotor symptom scale), and data about depressive symptoms (Beck’s depression inventory), cognition (Montreal cognitive assessment), HRQoL (Short-Form Health Questionnaire-36, SF-36), and medication knowledge (names, time of taking, indication, dosage) were assessed in 193 patients with PD. Multivariate analysis of variance (MANOVA), multivariate analysis of covariance, and mediation analyses were used to study the relationship between medication knowledge and HRQoL in combination with different mediators and covariates. Results Overall, 43.5% patients showed deficits in at least one of the 4 knowledge items, which was associated with higher age, number of medications per day and depression level, and poorer cognitive function, motor function, and lower education level. Using one-way MANOVA, we identified that medication knowledge significantly impacts physical functioning, social functioning, role limitations due to physical problems, and role limitations due to emotional problems. Mediation models using age, education level, and gender as covariates showed that the relationship between knowledge and SF-36 domains was fully mediated by Beck’s Depression Inventory but not by Montreal Cognitive Assessment. Conclusions Patients who expressed unawareness of their medication did not necessarily have cognitive deficits; however, depressive symptoms may instead be present. This concomitant depressive symptomatology is crucial in explaining the contribution of nonadherence and decreased medication knowledge to poor quality of life.

show abstract

“…Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease that severely affects the HRQoL of patients compared to healthy controls [ 6 ]. The correlates of poor HRQoL in PD patients are multifactorial and include demographics (such as age and gender), PD clinical characteristics (such as severity of motor and non-motor symptoms, PD subtypes, disease duration), adverse effects of treatment, comorbid conditions, and psychosocial function [ 7 – 9 ].…”

Section: Introductionmentioning

confidence: 99%

“…The correlates of poor HRQoL in PD patients are multifactorial and include demographics (such as age and gender), PD clinical characteristics (such as severity of motor and non-motor symptoms, PD subtypes, disease duration), adverse effects of treatment, comorbid conditions, and psychosocial function [ 7 – 9 ]. Both generic and PD-specific HRQoL tools have been used in PD patients [ 3 , 6 , 10 – 13 ]. Among the currently available PD-specific HRQoL tools, the Parkinson’s disease questionnaire-39 item (PDQ-39) that contains 39 items that are grouped under 8 domains, and its shorter version PDQ-8 that contains 8 items, each representing a domain of the PDQ-39 are more widely used [ 10 , 14 – 17 ].…”

Section: Introductionmentioning

confidence: 99%

“…For instance, sleep disorders stand out among non-motor symptoms, given their high prevalence and severe impact on cognitive function and HRQoL [ 28 , 30 – 33 ]. Ιncreasing evidence suggests that sleep problems and non-motor symptom burden do not only correlate with HRQoL assessments, but can also be predictive of longitudinal ΗΡQoL change in PD patients [ 6 , 23 , 24 , 34 – 37 ]. In addition, poor sleep quality in PD is associated with depression, anxiety and advanced disease [ 36 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation and validation of a patient-reported quality-of-life questionnaire for Parkinson’s disease

Stathis¹,

Papadopoulos²

2022

J Patient Rep Outcomes

View full text Add to dashboard Cite

Background Parkinson’s disease (PD) is a chronic, progressive illness with a profound impact on the health-related quality of life (HRQoL). Disease-specific patient-reported HRQoL measures, such as PDQ-39 and its short version PDQ-8, are increasingly used in clinical practice to address the consequences of PD on everyday life. Due to limitations in the content, especially in non-motor symptoms and sleep disturbances of PDQ-8, PDQoL7, a 7-item, short-term, self-reported, PD-specific HRQoL questionnaire was developed. Methods A representative sample of 60 adults with idiopathic PD completed the PDQoL7 questionnaire and the existing validated PDQ-8 and EQ-5D-5L questionnaires (all in Greek). Results PDQoL7 summary index strongly correlated with PDQ-8 (rs = 0.833, P < 0.001) and EQ-5D-5L (rs = − 0.852, P < 0.001). The correlation between PDQoL7 and EQ-5D-5L was statistically significantly stronger compared to PDQ-8 and EQ-5D-5L (rs = − 0.852 vs rs = − 0.789 respectively, P < 0.001). The internal consistency of PDQoL7 was not affected by item deletion (positive item to total correlations: 0.29–0.63). No redundant items (with inter-item correlation coefficients greater than 0.80) were identified. Cronbach’s α for PDQoL7 was comparable to PDQ-8 (0.804 versus 0.799 respectively). As PDQoL7 had three-dimensional structure, omega coefficient analysis confirmed its reliability (omega total: 0.88; omega hierarchical: 0.58). Conclusions PDQoL7 is an acceptable, easy to use, valid and reliable tool for the determination of HRQoL in PD patients that is potentially more comprehensive than PDQ-8 based on the available evidence. PDQoL7 could allow for a more thorough evaluation of the impact of PD and contribute to guiding healthcare decisions. This will be confirmed in subsequent analysis on larger patient cohorts.

show abstract

Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

Cited by 69 publications

References 79 publications

Effect of Cerebral Microbleeds on Cognitive Function and Quality of Life in Parkinson Disease

Effect of Cerebral Microbleeds on Cognitive Function and Quality of Life in Parkinson Disease

The impact of poor medication knowledge on health-related quality of life in people with Parkinson’s disease: a mediation analysis

Evaluation and validation of a patient-reported quality-of-life questionnaire for Parkinson’s disease

Contact Info

Product

Resources

About